68100-63-0

Upstream product

• 109-76-2 Trimethylenediamine 
• 1885-29-6 anthranilic acid nitrile 
• 90312-02-0 N-(2-hydroxymethylphenyl)-4-methylbenzenesulfonamide 
• 6590-65-4 N-(2-Formyl-phenyl)-4-methyl-benzenesulfonamide 
• 1266834-96-1 2-[2-N-(p-toluenesulfonylamino)phenyl]-1,4,5,6-tetrahydropyrimidine 
• 5344-90-1 2-Aminobenzyl alcohol 
• 88-17-5 2-(trifluoromethyl)benzenamine 
• 132608-43-6 [3,4-Dihydro-2H-naphthalen-(1E)-ylidene]-[2-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-phenyl]-amine 
• 137434-39-0 (E)-N-(1,2,3,4-tetrahydronaphthalen-1-ylidene)-2-(trifluoromethyl)aniline 

Relevant academic research and scientific papers

Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)

The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in many disease states, including tumor cells, either by growth factor receptor tyrosine kinases or by the genetic mutation and amplification of key pathway components. A variety of PI3K isoforms play differential roles in cancers. As such, the development of PI3K inhibitors from novel compound classes should lead to differential pharmacological and pharmacokinetic profiles and allow exploration in various indications, combinations, and dosing regimens. A screening effort aimed at the identification of PI3Kγ inhibitors for the treatment of inflammatory diseases led to the discovery of the novel 2,3-dihydroimidazo[1,2-c]quinazoline class of PI3K inhibitors. A subsequent lead optimization program targeting cancer therapy focused on inhibition of PI3Kα and PI3Kβ. Herein, initial structure–activity relationship findings for this class and the optimization that led to the identification of copanlisib (BAY 80-6946) as a clinical candidate for the treatment of solid and hematological tumors are described.

Investigations of possible prodrug structures for 2-(2-mercaptophenyl)tetrahydropyrimidines: Reductive conversion from anti-HIV agents with pyrimidobenzothiazine and isothiazolopyrimidine scaffolds

3,4-Dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (PD 404182) and 3,4-dihydro-2H-benzo[4,5]isothiazolo[2,3-a]pyrimidine are the heterocyclic antiretroviral agents against human immunodeficiency virus type 1 (HIV-1) infection. On the basis of simi

Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3] benzothiazin-6-imines and related tricyclic heterocycles

3,4-Dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (PD 404182) is a virucidal heterocyclic compound active against various viruses, including HCV, HIV, and simian immunodeficiency virus. Using facile synthetic approaches that we developed for the synthesis of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic derivatives, the parallel structural optimizations of the central 1,3-thiazin-2-imine core, the benzene part, and the cyclic amidine part of PD 404182 were investigated. Replacement of the 6-6-6 pyrimido[1,2-c][1,3] benzothiazin-6-imine framework with 5-6-6 or 6-6-5 derivatives led to a significant loss of anti-HIV activity, and introduction of a hydrophobic group at the 9- or 10-positions improved the potency. In addition, we demonstrated that the PD 404182 derivative exerts anti-HIV effects at an early stage of viral infection.

A NOVEL ROUTE TO 7-(SUBSTITUTED AMINO)-5,6-DIHYDROBENZACRIDINES

The title compounds (3) are produced in a novel, lithium alkylamide- and dialkylamide-mediated cyclization of N-(1,2,3,4-tetrahydro-1-naphthylidene)-2-trifluoromethylaniline (2).The mechanism of this unusual transformation that involves the trifluoromethyl group is discussed.

An Activated Trifluoromethyl Group as a New Synthon for 4,5-Dihydro-1H-imidazole and 1,4,5,6-Tetrahydropyrimidine Systems

Treatment of 4-(trifluoromethyl)benzenamine 1a and 2-(trifluoromethyl)benzenamine 1b with lithium 2-aminoethylamide gives 2-(4-aminophenyl)-4,5-dihydro-1H-imidazole 3a and 2-(2-aminophenyl)-4,5-dihydro-1H-imidazole 3b, respectively.Similar reactions of 1a